AU681362B2 - OP-3-induced morphogenesis - Google Patents

OP-3-induced morphogenesis

Info

Publication number
AU681362B2
AU681362B2 AU55900/94A AU5590094A AU681362B2 AU 681362 B2 AU681362 B2 AU 681362B2 AU 55900/94 A AU55900/94 A AU 55900/94A AU 5590094 A AU5590094 A AU 5590094A AU 681362 B2 AU681362 B2 AU 681362B2
Authority
AU
Australia
Prior art keywords
amino acid
seq
species
tissue
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU55900/94A
Other languages
English (en)
Other versions
AU5590094A (en
Inventor
Charles M. Cohen
Thangavel Kuberasampath
Hermann Oppermann
Engin Ozkaynak
Roy H. L. Pang
David C. Rueger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stryker Corp
Original Assignee
Creative Biomolecules Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creative Biomolecules Inc filed Critical Creative Biomolecules Inc
Publication of AU5590094A publication Critical patent/AU5590094A/en
Application granted granted Critical
Publication of AU681362B2 publication Critical patent/AU681362B2/en
Assigned to STRYKER CORPORATION reassignment STRYKER CORPORATION Alteration of Name(s) in Register under S187 Assignors: CREATIVE BIOMOLECULES, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/50—Preparations specially adapted for dental root treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU55900/94A 1992-11-03 1993-11-02 OP-3-induced morphogenesis Ceased AU681362B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97109192A 1992-11-03 1992-11-03
US971091 1992-11-03
US2933593A 1993-03-04 1993-03-04
US4051093A 1993-03-31 1993-03-31
PCT/US1993/010520 WO1994010203A2 (en) 1992-11-03 1993-11-02 Op-3-induced morphogenesis

Publications (2)

Publication Number Publication Date
AU5590094A AU5590094A (en) 1994-05-24
AU681362B2 true AU681362B2 (en) 1997-08-28

Family

ID=27363460

Family Applications (1)

Application Number Title Priority Date Filing Date
AU55900/94A Ceased AU681362B2 (en) 1992-11-03 1993-11-02 OP-3-induced morphogenesis

Country Status (5)

Country Link
EP (1) EP0672064A1 (de)
JP (1) JPH08503198A (de)
AU (1) AU681362B2 (de)
CA (1) CA2147598A1 (de)
WO (1) WO1994010203A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972703A (en) * 1994-08-12 1999-10-26 The Regents Of The University Of Michigan Bone precursor cells: compositions and methods
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US6281195B1 (en) † 1997-02-07 2001-08-28 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
US20010016646A1 (en) 1998-03-20 2001-08-23 David C. Rueger Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects
US7041641B2 (en) 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
EP0980252B1 (de) 1997-05-05 2004-10-06 Curis, Inc. Therapien zur behandlung von akutem nierenversagen
US20030032586A1 (en) * 1997-05-15 2003-02-13 David C. Rueger Compositions for morphogen-induced osteogenesis
WO1998054572A1 (en) 1997-05-30 1998-12-03 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
DE602005022998D1 (de) 2004-03-10 2010-09-30 Scil Technology Gmbh Überzogene implantate, ihre herstellung und verwendung davon
WO2005115438A1 (en) 2004-05-25 2005-12-08 Stryker Corporation Use of morphogenic proteins for treating cartilage defects
WO2007142818A2 (en) 2006-05-17 2007-12-13 Stryker Corporation Use of a soluble morphogenic protein complex for treating cartilage defects
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
AU2007339280B2 (en) 2006-12-21 2013-12-05 Stryker Corporation Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
EP2187932B1 (de) 2007-08-07 2015-01-28 DePuy Synthes Products, LLC Proteinformulierungen mit gdf-5 in wässriger saurer lösung
CA2718592A1 (en) 2008-02-13 2009-08-20 Keith Hruska Method of treating vascular sclerosis
CN102026619A (zh) 2008-04-14 2011-04-20 先进科技及再生医学有限责任公司 液体缓冲的gdf-5制剂
JP5819733B2 (ja) 2009-02-12 2015-11-24 ストライカー コーポレイションＳｔｒｙｋｅｒ Ｃｏｒｐｏｒａｔｉｏｎ 障害および疾患に対する全身治療のためのＴＧＦ−βスーパーファミリーメンバー含有タンパク質の末梢投与
AU2010213591B2 (en) 2009-02-12 2013-11-21 Stryker Corporation Compositions and methods for minimally-invasive systemic delivery of proteins including TGF-beta superfamily members
US20120148539A1 (en) 2009-03-24 2012-06-14 Moulay Hicham Alaoui-Ismaili Methods and Compositions for Tissue Engineering
WO2011031856A1 (en) 2009-09-09 2011-03-17 Stryker Corporation Bmp -7 for use in treating pain induced by injuries and diseases of an articular joint
ES2387379T3 (es) 2009-09-17 2012-09-21 Stryker Corporation Tampones para controlar el pH de las proteínas morfogenéticas óseas
WO2011087768A1 (en) 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
ITMI20112437A1 (it) * 2011-12-30 2013-07-01 Bionest Ltd Uso di citochine, fattori di crescita e fattori antibatterici come materiale di sottofondo di cavita' per la terapia della carie penetrante dei denti e dell'infiammazione pulpare
DK2797609T3 (en) 2011-12-30 2017-01-09 Innomed S A COMBINING growth factors, cytokines, anti-bacterial / ANTIVIRALS FACTORS STEM CELL-STIMULATING FACTORS, complement C3A / C4A, immunoglobulins, and chemotactic factors
EP2797610A1 (de) 2011-12-30 2014-11-05 BIONEST Ltd. Kombination aus wachstumsfaktoren, cytokinen, antibakteriellen/antiviralen faktoren, stammzellenstimulierenden faktoren, komplementproteine c3a/c4a und chemotaktische faktoren

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU678380B2 (en) * 1992-07-31 1997-05-29 Stryker Corporation Morphogenic protein soluble complex and composition thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338663C (en) * 1988-04-08 1996-10-22 Hermann Oppermann Biosynthetic osteogenic proteins and osteogenic devices containing them
US5106626A (en) * 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US5011961A (en) * 1990-06-13 1991-04-30 Dow Corning Limited Method of making organosilbutadiyne polymers
WO1992015323A1 (en) * 1991-03-11 1992-09-17 Creative Biomolecules, Inc. Protein-induced morphogenesis
ES2253736T3 (es) * 1991-08-30 2006-06-01 Curis, Inc. Tratamiento para prevenir la perdida y/o aumentar la masa osea en transtornos metabolicos del hueso.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU678380B2 (en) * 1992-07-31 1997-05-29 Stryker Corporation Morphogenic protein soluble complex and composition thereof

Also Published As

Publication number Publication date
AU5590094A (en) 1994-05-24
WO1994010203A2 (en) 1994-05-11
CA2147598A1 (en) 1994-05-11
WO1994010203A3 (en) 1994-08-18
JPH08503198A (ja) 1996-04-09
EP0672064A1 (de) 1995-09-20

Similar Documents

Publication Publication Date Title
AU681362B2 (en) OP-3-induced morphogenesis
AU660019B2 (en) Protein-induced morphogenesis
US6333312B1 (en) Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US6800603B2 (en) Morphogen-induced neural cell adhesion
US6153583A (en) OP-3 induced morphogenesis
AU668411B2 (en) Prosthetic devices having enhanced osteogenic properties
AU681594B2 (en) Morphogen-induced nerve regeneration and repair
US6495513B1 (en) Morphogen-enhanced survival and repair of neural cells
US6949505B1 (en) Morphogen-induced dendritic growth
WO1993005751A2 (en) Osteogenic proteins in the treatment of bone deseases
US5652118A (en) Nucleic acid encoding a novel morphogenic protein, OP-3
US20030105004A1 (en) Novel morphogenic protein compositions of matter
AU4795193A (en) Morphogenic protein soluble complex and composition thereof
AU5162393A (en) Morphogen-induced liver regeneration
AU2862492A (en) Morphogenic protein screening method
WO1994006399A1 (en) Morphogen-induced periodontal tissue regeneration
US6211146B1 (en) 60A protein-induced morphogenesis
AU5290893A (en) Morphogen treatment of gastrointestinal ulcers
US20030224979A1 (en) Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
AU670558C (en) Osteogenic proteins in the treatment of bone diseases
AU670334B2 (en) Morphogen-induced periodontal tissue regeneration
WO1994006447A2 (en) 60a protein-induced morphogenesis

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired